Q2 2025 Aurora Spine Corp Earnings Call Transcript
Key Points
- Aurora Spine Corp (ASAPF) reported a 10.2% increase in revenues for the second quarter of 2025 compared to the same period last year.
- The company's gross margins improved to 62.2% in the second quarter, up from 58% in the previous year.
- The SiLO TFX system saw a significant revenue increase of 32.8% from the second quarter of the previous year.
- Aurora Spine Corp (ASAPF) successfully launched the FDA-cleared Hydra A.E.R.O. product, with initial surgeries showing positive performance.
- The DEXA-C product sales increased by 70% during the first half of 2025, demonstrating successful market penetration.
- Aurora Spine Corp (ASAPF) reported a net loss of $199,000 for the second quarter of 2025, compared to a net loss of $154,000 in the same period last year.
- Operating expenses increased to approximately $3 million in the second quarter of 2025, up from $2.7 million in the previous year.
- The company is experiencing longer sales cycles to onboard new doctors, which may impact short-term revenue growth.
- Sales of the Hydra pedicle screws have not met expectations, and the company is working to increase traction in this area.
- The retooling of the Apollo Cervical Plate has slowed down some sales, impacting the overall performance of the cervical product line.
Good day. Welcome to the Aurora Spine second-quarter financial year 2025 results conference call.
(Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Adam Lowensteiner, Vice President of Lytham Partners. Please go ahead, sir.
Thank you, [Chuck]. Welcome, everyone. Thank you for joining us today to conduct an update with investors and review the financial results for Aurora Spine for the second-quarter fiscal year 2025 that ended June 30, 2025.
With us on the call representing the company today are Trent Northcutt, President and CEO; Chad Clouse, Chief Financial Officer; and Matt Goldstone, Chief Commercial Officer.
Before we begin, I would like to remind everyone that statements made during the course of this call may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934. These statements reflect
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
